AMENDMENTS TO THE CLAIMS

1. – 46. (cancelled)

47. (Currently amended) A method for the treatment of male erectile dysfunction which comprises administering to a male in need thereof a pharmacologically effective amount of a composition comprising an α-adrenergic blocker and a prostaglandin in a buffer, wherein the buffer comprises ~~a substrate for nitric oxide synthetase~~ L-arginine and glycine and has a pH range of from about 3 to about 5.

48. (Previously Presented) The method of claim 47 wherein the α-adrenergic blocker is phentolamine mesylate, or any pharmaceutically acceptable salt thereof.

49. (Previously Presented) The method of claim 47 wherein the prostaglandin is alprostadil.

50. (Previously Presented) The method of claim 47 wherein the α-adrenergic blocker is phentolamine mesylate, or any pharmaceutically acceptable salt thereof and the prostaglandin is alprostadil, and wherein the composition is administered in one or more dosages.

51. (Canceled)

52. (Canceled)

53. (Canceled)

54. (Previously Presented) The method of claim 47 wherein the buffer comprises glycine and L-arginine in a weight ratio of about 1:20.

55. (Currently Amended) The method of claim [[53]] 47 wherein the buffer further comprises benzyl alcohol and mannitol and has a pH range of from about 3 to about 5.

56. (Previously Presented) The method of claim 50 wherein the weight ratio of phentolamine mesylate: alprostadil is about 0.5:0.005 to about 5: 0.20.

57. (Previously Presented) The method of claim 50 wherein the weight ratio of phentolamine mesylate: alprostadil is about 1:0.01.

58. (Currently Amended) The method of claim 50 wherein the dosage of phentolamine mesylate and alprostadil is less than ~~about~~ 40 μg/ml alprostadil and less than ~~about~~ 10 mg/ml phentolamine.

59. (Previously Presented) The method of claim 58 wherein the dosage of phentolamine mesylate and alprostadil are in the range of about 1.25-5 mg/ml phentolamine and about 5-20 μg/ml alprostadil.

60. (Previously Presented) The method of claim 58 wherein the dosage of phentolamine mesylate and alprostadil are about 1 mg/ml phentolamine and about 0.01 mg/ml alprostadil.

61. (Previously Presented) The method of claim 58 wherein the dosage of phentolamine mesylate and alprostadil is present in a total volume of 0.5 ml.

62. (Previously Presented) The method of claim 50 wherein the dosage of alprostadil is about 5 μg/ml in a total volume of 0.5 ml.

63. (Previously Presented) The method of claim 50 wherein the dosage of phentolamine is about 1.25 mg/ml in a total volume of 0.5 ml.

64. (Canceled)